SEC EDGARAUG 131 min read$TAK

Pignagnoli Agosti Marcello sold $393K of TAK

Pignagnoli Agosti Marcello (Head, Strat. & Port. Dev) sold 22,957 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.39M total) on 2026-08-10.

Original reporting

SEC EDGAR · Pignagnoli Agosti Marcello

Published Aug 13, 2026, 1:46 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 13, 2026, 2:02 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TAK

Neutral

medium confidence

Mentioned

$TAK

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TAKNeutralLow

Why it matters

The newest fact is the specific open-market sale: 22,957 shares sold at $17.10 each, totaling about $392.6K, with remaining holdings of 176,977 shares.

Market read

Traders may note insider selling as a minor sentiment datapoint, but there is no accompanying fundamental catalyst in the text.

What to watch

The article provides only the sale transaction; it does not include any concurrent buy, option activity, or company news that would connect the sale to a new fundamental thesis.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Takeda Pharmaceutical Co Ltd.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TAKNeutralMedium confidence

Context

Insider Form 4 shows Takeda’s head of strategy and portfolio development sold 22,957 shares at $17.10 on 2026-08-10.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, not guidance, earnings, or a corporate event. The disclosed details (sale size, price, post-sale holdings) are specific, but insider sales are typically not predictive without accompanying company-specific news.

Market effects

Sector

No clear sector read-through; this is company-specific insider selling without new operational or regulatory information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a disclosed 10b5-1 plan could be interpreted as discretionary selling, but insider sales often reflect diversification or personal liquidity needs rather than bearish expectations.

Key entities

issuer
TAK
Takeda Pharmaceutical Co Ltd, the company whose insider transaction is disclosed.
insider
Pignagnoli Agosti Marcello
Head, Strategy and Portfolio Development, reporting an open-market sale.

Read at source ← All news

OCT 6

$TAKMedAI 9/10

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

Zasocitinib, an investigational TYK2 inhibitor by Takeda, showed superior efficacy in treating plaque psoriasis compared to deucravacitinib in a phase 3 trial. 36.5% of patients achieved PASI 100 with zasocitinib vs. 13.9% with deucravacitinib. The drug's higher TYK2 selectivity and longer IL-23 blockade were cited as key factors. Zasocitinib is under review by the FDA and EMA.

hcplive.com2 min

OCT 3

$PFEHighAI 9/10

Targeted Drug Duo with Lighter Chemotherapy Delivers 97% Survival in

A phase 2 trial showed a regimen combining brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved 92% complete response and 97% 2-year progression-free survival in early-stage Hodgkin lymphoma. The study, published in Advances in Therapy, involved 154 patients and was funded by Seagen (now Pfizer), Takeda, and Bristol-Myers Squibb.

bioengineer.org3 min

OCT 2

$BIIBMed

CMS's GLOBE Drug Pricing Plan Collapses to $400M in Savings, Leaving a Four-Company Test

CMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.

finance.biggo.com4 min

SEP 30

$TAKHighAI 9/10

Oveporexton Improves Wakefulness and Cataplexy in Narcolepsy Type 1

Takeda's Oveporexton (Orzeyful) significantly improved wakefulness, daytime sleepiness, and cataplexy in narcolepsy type 1 patients over 12 weeks, according to two phase 3 trials. The FDA approved the drug in August 2026, positioning it as the first therapy addressing orexin deficiency. Adverse events included increased urinary frequency and transient insomnia. Trials showed mean sleep latency improvements of 14.3 to 19.8 minutes with Oveporexton vs. placebo.

ajmc.com3 min

SEP 30

$TAKMedAI 8/10

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda announced Phase 3 trial results showing zasocitinib (TAK-279) demonstrated superior efficacy in treating moderate-to-severe plaque psoriasis compared to deucravacitinib. Key data: 36.5% of patients achieved complete skin clearance (PASI 100) at week 16 vs. 13.9% for deucravacitinib. Zasocitinib also showed durable skin clearance and improvements in itch and quality of life. The drug is under regulatory review for psoriasis treatment.

intelligencer.ca2 min

SEP 22